TITLE

Safety of Inhaled Anticholinergics for COPD Scrutinized

AUTHOR(S)
Elliott, William T.
PUB. DATE
November 2008
SOURCE
Travel Medicine Advisor;Nov2008 Pharmacology Watch, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the governmental investigation into the safety of inhaled anticholinergics for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S. in 2008. The Food and Drug Administration has reportedly issued a report on the ongoing safety review of tiotropium. It references studies that demonstrated the association between increased risk of mortality and cardiovascular disease in COPD patients and inhaled anticholinergics.
ACCESSION #
35130414

 

Related Articles

  • Safety of Inhaled Anticholinergics for COPD Scrutinized. Elliott, William T. // Primary Care Reports;Nov2008 Pharmacology Watch, p1 

    The article considers the safety of inhaled anticholinergics for the treatment of chronic obstructive pulmonary disease (COPD), which was prompted by a communication from the U.S. Food and Drug Administration (FDA) regarding the safety review of tiotropium. Two studies linking inhaled...

  • Fresh from the pipeline: Tiotropium bromide. Mundy, Cynthia; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Aug2004, Vol. 3 Issue 8, p643 

    In January 2004, tiotropium bromide (Spiriva; Boehringer Ingelheim/Pfizer), an orally inhaled anticholinergic drug, was approved by the US FDA for the treatment of chronic obstructive pulmonary disease. Is it likely to become the bronchodilator of choice for this common and increasingly...

  • Congress asks for investigation of FDA resources and staffing. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);3/8/2008, Vol. 336 Issue 7643, p525 

    The article focuses on investigation which have been asked for by committees of the U.S. Congress in 2008. The investigation has been requested to determine whether the U.S. Food and Drug Administration (FDA) has the resources and staffing which is necessary to do its job of protecting the U.S....

  • Cosmetic ingredients under scrutiny. Duckett, Michaela L. // Charlotte Post;11/8/2012, Vol. 38 Issue 9, p1B 

    The article reports that the U.S. Federal Food and Drug Administration is investigating the safety and effectiveness of ingredients used in cosmetics.

  • Safety of Inhaled Anticholinergics for COPD Scrutinized. Elliott, William T. // Infectious Disease Alert;Nov2008 Pharmacology Watch, p1 

    The article focuses on controversies surrounding the safety of inhaled anticholinergics administration for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S. In July 2008, the Food and Drug Administration (FDA) issued an Early Communication for the safety review of...

  • Asthma news in 2010. Tanzi, Maria G. // Pharmacy Today;Dec2010, Vol. 16 Issue 12, p36 

    The article discusses various issues related to asthma management in the U.S. Pharmacist Devra Dang states that the general medical community and patients are focusing on assessing asthma control and severity . The Food and Drug Administration (FDA) has released safety communication concerning...

  • Safety of Inhaled Anticholinergics for COPD Scrutinized.  // OB/GYN Clinical Alert;Nov2008 Pharmacology Watch, p1 

    The article offers news briefs related to pharmacology in the U.S. The Food and Drug Administration (FDA) has issued an "Early Communication" about an ongoing safety review of tiotropium (Spriva®), an inhaled anticholinergic for treating chronic obstructive pulmonary disease (COPD)....

  • Safety of Inhaled Anticholinergics for COPD Scrutinized.  // Neurology Alert;Nov2008 Pharmacology Watch, p1 

    The article reports on the Early Communication issued by the U.S. Food and Drug Administration (FDA) in July 2008 concerning the ongoing safety review of tiotropium drug for the treatment of chronic obstructive pulmonary disease (COPD). Said review aims to investigate the possible association of...

  • FDA Postmarket Overhaul Progress Slow.  // BioWorld Today;12/10/2009, Vol. 20 Issue 237, p4 

    The article reports that the Food and Drug Administration (FDA) in the U.S. has been slow in restructuring oversight regarding postmarket drug safety wherein weaknesses were discovered by the Government Accountability Office (GAO), according to congressional investigators. The investigation...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics